Novo Nordisk reports positive data from new Tresiba diabetes trial

Novo Nordisk has reported new clinical trial data that demonstrates the benefits of its U200 formulation of the type 2 diabetes drug Tresiba.

Results presented at the annual meeting of the European Association for the Study of Diabetes has shown that patients receiving this version of Tresiba experienced significantly lower rates of confirmed hypoglycaemia and reduced mean fasting blood glucose compared to those on insulin glargine U100.

They also reported higher satisfaction, fewer cases of nocturnal hypoglycaemia and lower weight change, as well as rating the delivery device FlexTouch to be significantly better for function.

Tresiba U200 is twice as concentrated as U100, allowing patients to inject up to 160 units in a single injection, rather than in two separate injections.

Dr Mark Warren, lead study investigator for Novo Nordisk, said: "These findings provide valuable insights to physicians treating patients with type 2 diabetes, many of whom require higher doses of insulin."

Tresiba was launched worldwide last year, with a paediatric indication for the drug being approved in Europe earlier this year.